BIOGNOSYS
15.6.2021 08:02:08 CEST | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for life sciences research and development, announced today the launch of Spectronaut 15 . The software provides fast, robust, and seamless data analysis for mass spectrometry (MS) based data-independent acquisition (DIA) proteomics . Thus, Spectronaut enables the investigation of protein expression, function, and structure across all major biological species and sample types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005013/en/
Spectronaut is a commercial software for industry and academia and is also used as part of Biognosys' discovery proteomics contract research services. In conjunction with the company's proprietary, patented Hyper Reaction Monitoring (HRM™) technology, Spectronaut enables reproducible and precise quantification of up to 10,000 proteins in large-scale studies . The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for R&D and clinical research.
Since its first release in 2003, Spectronaut is continuously improving and always supports the newest technologies in data acquisition. The 15th generation of the software comes with an array of novel features and updates , such as:
- Significant improvements to directDIA, the industry-leading library-free DIA workflow
- A more comprehensive toolset for post-translational modification (PTM) analysis
- Improved deep learning augmentation for immunopeptidomics and ion mobility data analysis
- Powerful data visualization in an intuitive user interface
"With this new Spectronaut release, we offer our software users and service customers once more a higher level of performance, user experience, and insights to support their discovery proteomics research", said Biognosys CTO Lukas Reiter, PhD .
Spectronaut lead developer Oliver M. Bernhardt will share more details on the new features during the Spectronaut 15 launch webinar , Expand Biological insights with DIA Proteomics , held today at 5 PM CEST. Beyond that, Guest speaker Andreas-David Brunner will present a robust and scalable single-cell DIA proteomics workflow using ion mobility technology (dia-PASEF), developed at the Max Planck Institute of Biochemistry (Matthias Mann Lab).
Spectronaut 15 is fully vendor-independent and compatible with proteomics data acquired on instruments of all major mass spectrometer vendors.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
"Spectronaut has made it possible to implement our breakthrough dia-PASEF technology in many of our customer's facilities. With the latest Spectronaut release, the support for our ion mobility technology has seen a significant improvement, and we are looking forward to continuing our collaboration with Biognosys to maintain Spectronaut as a key solution for Bruker's DIA workflows."
Andreas Huhmer, Director Marketing, Mass Spectrometry Solutions at Thermo Fisher Scientific:
"Biognosys' Spectronaut is our software of choice to analyze DIA data in internal projects, including acquisition method development. Of course, it is also the solution we strongly recommend to our customers. Spectronaut has always been at the forefront when it comes to supporting our technology, and its ease of use and versatility makes it the best partner for DIA data analysis."
For more information about Spectronaut, including details about free trials and pricing, please visit biognosys.com/spectronaut .
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys' unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at www.biognosys.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 11:00:00 CEST | Press release
Acquisition adds widely adopted data observability and reliability capabilities to the Boomi Enterprise Platform, giving enterprises the data quality and governance required to operationalize AI Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key TakeawaysWhat Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-sou
Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 10:00:00 CEST | Press release
Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom